Yüklüyor......
PD-1/PD-L1 axis in lung cancer
Cancer immunotherapies have revolutionized the treatment of non-small cell lung cancer. Yet, only a small subset of patients will benefit from PD-(L)1 blockade. PD-L1 tumor cell expression is the only approved biomarker at present. Tumor mutational burden and other emerging biomarkers should improve...
Kaydedildi:
| Yayımlandı: | Cancer J |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5784856/ https://ncbi.nlm.nih.gov/pubmed/29360723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000300 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|